Date: 2013-10-01
Type of information: Distribution agreement
Compound: ConfirmMDx™ for prostate cancer test
Company: MDX Health (Belgium) FedMed (USA) ACPN (USA)
Therapeutic area: Cancer - Oncology
Type agreement: distribution
commercialisation
Action mechanism: ConfirmMDx for Prostate Cancer is an epigenetic assay to help distinguish patients who have a true-negative biopsy from those at risk for occult cancer. The test helps urologists rule out prostate cancer-free men from undergoing unnecessary repeat biopsies and, helps rule in high risk patients who may require repeat biopsies and potential treatment.
Disease: prostate cancer
Details: * On October 1, 2013, MDxHealth, a molecular diagnostics company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, has announced that it has expanded access to ConfirmMDx for Prostate Cancer by signing agreements with health insurance providers FedMed and ACPN. These agreements provide FedMed (40M) and ACPN (11.2M) members, consisting of insurance carriers, third party administrators, health and welfare funds and self-insured health plans, with access to the ConfirmMDx test.
Financial terms:
Latest news:
